Keros Therapeutics harnesses the knowledge of leading physician researchers and medical experts in the discovery and development of novel proprietary therapeutics for neuromuscular diseases. Headquartered in Lexington, Massachusetts, Keros Therapeutics is led by President and CEO Dr. Jasbir Seehra, who has over three decades of hands-on experience creating first-tier drug therapies. An expert in both biologic and small-molecule drug development, Dr. Seehra leads the Keros team as it explores approaches to treating some of the most intractable neuromuscular diseases, such as fibrodysplasia ossificans progressiva (FOP). The innovative work Keros Therapeutics is pursuing could bring relief to those who suffer from rare and ultra-rare neuromuscular diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/19 | $23,000,000 | Series B |
Arkin Bio Ventures Global Health Science Fund Medison Pharma Partners Innovation Fund Pontifax | undisclosed |
